Pancreatic neuroendocrine tumor (pNET), well-differentiated G1/G2 · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-MEN4-CARRIER-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-20 \| pending_clinical_signoff
Diseases	`DIS-PNET`
Sources	`SRC-NCCN-NET-2025`

Notes

STUB — Wave O confirmed-carrier surveillance pathway (MEN4 / CDKN1B). Two-Clinical-Co-Lead signoff queued per CHARTER §6.1 dev-mode. Sibling — IND-MEN4-CARRIER-INTENSIFIED (aggressive plan_track).

Used By

Indication

IND-MEN4-CARRIER-INTENSIFIED - IND-MEN4-CARRIER-INTENSIFIED

Red flag

RF-MEN4-CONFIRMED-CARRIER - Confirmed germline pathogenic / likely-pathogenic variant in CDKN1B (p27/Kip1) — Multiple...